304 related articles for article (PubMed ID: 19703994)
1. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.
Cerna D; Li H; Flaherty S; Takebe N; Coleman CN; Yoo SS
J Biol Chem; 2012 Jun; 287(26):22408-17. PubMed ID: 22570471
[TBL] [Abstract][Full Text] [Related]
3. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
[TBL] [Abstract][Full Text] [Related]
4. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
6. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
Olesen UH; Thougaard AV; Jensen PB; Sehested M
Mol Cancer Ther; 2010 Jun; 9(6):1609-17. PubMed ID: 20515945
[TBL] [Abstract][Full Text] [Related]
7. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
Shames DS; Elkins K; Walter K; Holcomb T; Du P; Mohl D; Xiao Y; Pham T; Haverty PM; Liederer B; Liang X; Yauch RL; O'Brien T; Bourgon R; Koeppen H; Belmont LD
Clin Cancer Res; 2013 Dec; 19(24):6912-23. PubMed ID: 24097869
[TBL] [Abstract][Full Text] [Related]
8. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Chan M; Gravel M; Bramoullé A; Bridon G; Avizonis D; Shore GC; Roulston A
Cancer Res; 2014 Nov; 74(21):5948-54. PubMed ID: 25145669
[TBL] [Abstract][Full Text] [Related]
9. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
11. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
[TBL] [Abstract][Full Text] [Related]
12. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
Zhao G; Green CF; Hui YH; Prieto L; Shepard R; Dong S; Wang T; Tan B; Gong X; Kays L; Johnson RL; Wu W; Bhattachar S; Del Prado M; Gillig JR; Fernandez MC; Roth KD; Buchanan S; Kuo MS; Geeganage S; Burkholder TP
Mol Cancer Ther; 2017 Dec; 16(12):2677-2688. PubMed ID: 29054982
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
15. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
[TBL] [Abstract][Full Text] [Related]
16. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
Kato H; Ito E; Shi W; Alajez NM; Yue S; Lee C; Chan N; Bhogal N; Coackley CL; Vines D; Green D; Waldron J; Gullane P; Bristow R; Liu FF
Clin Cancer Res; 2010 Feb; 16(3):898-911. PubMed ID: 20103674
[TBL] [Abstract][Full Text] [Related]
18.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
19. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
[TBL] [Abstract][Full Text] [Related]
20. Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation.
Kraus D; Reckenbeil J; Veit N; Kuerpig S; Meisenheimer M; Beier I; Stark H; Winter J; Probstmeier R
Cell Oncol (Dordr); 2018 Oct; 41(5):485-494. PubMed ID: 29949049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
